Contrast-enhanced cardiovascular magnetic resonance in the hyperacute phase of ST-elevation myocardial infarction

  • Eric Larose
  • Julie Côté
  • Josep Rodés-Cabau
  • Bernard Noël
  • Gerald Barbeau
  • Edith Bordeleau
  • Santiago Miró
  • Bernard Brochu
  • Robert Delarochellière
  • Olivier F. Bertrand
Original paper


Cardiovascular magnetic resonance (CMR) very early after primary percutaneous coronary intervention (PPCI) may lead to instability or early stent complications. However, CMR in the hyperacute phase of STEMI may improve risk stratification. We investigated feasibility and safety of CMR in the hyperacute phase of STEMI immediately after PPCI. One hundred and twenty eight consecutive patients immediately after PPCI for STEMI. Sixty four underwent CMR <12 h after PPCI versus 64 matched controls. Outcomes were followed over 6 months. CMR in hyperacute STEMI was not associated with in-hospital death, infarct expansion, or urgent revascularization (P = NS). CMR (32 ml gadolinium contrast) immediately after PPCI (180 ml iodine contrast) did not increase nephropathy. CMR did not increase major adverse cardiac events (5 vs. 8%, P = 0.16) or recurrence of angina (6 vs. 8%, P = 0.73) at 6 months. CMR immediately after PPCI is feasible and safe, allowing very early risk stratification in STEMI.


Acute myocardial infarction Magnetic resonance imaging Primary coronary angioplasty Contrast nephropathy Safety 


  1. 1.
    Yan AT, Shayne AJ, Brown KA et al (2006) Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 114:32–39. doi: 10.1161/CIRCULATIONAHA.106.613414 PubMedCrossRefGoogle Scholar
  2. 2.
    Braunwald E (2003) Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. Circulation 108:III28–III37. doi: 10.1161/01.CIR.0000086952.14979.32 PubMedCrossRefGoogle Scholar
  3. 3.
    Thiele H, Kappl MJ, Linke A et al (2007) Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. Eur Heart J 28:1433–1439. doi: 10.1093/eurheartj/ehm173 PubMedCrossRefGoogle Scholar
  4. 4.
    Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 110:e82–e292. doi: 10.1161/01.CIR.0000134791.68010.FA PubMedCrossRefGoogle Scholar
  5. 5.
    Briguori C, Colombo A, Airoldi F et al (2006) Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67:175–180. doi: 10.1002/ccd.20592 PubMedCrossRefGoogle Scholar
  6. 6.
    Rihal CS, Textor SC, Grill DE et al (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264. doi: 10.1161/01.CIR.0000016043.87291.33 PubMedCrossRefGoogle Scholar
  7. 7.
    Shellock FG (2002) Magnetic resonance safety update 2002: implants and devices. J Magn Reson Imaging 16:485–496. doi: 10.1002/jmri.10196 PubMedCrossRefGoogle Scholar
  8. 8.
    Friedrich MG, Strohm O, Kivelitz D et al (1999) Behaviour of implantable coronary stents during magnetic resonance imaging. Int J Cardiovasc Intervent 2:217–222PubMedGoogle Scholar
  9. 9.
    Gerber TC, Fasseas P, Lennon RJ et al (2003) Clinical safety of magnetic resonance imaging early after coronary artery stent placement. J Am Coll Cardiol 42:1295–1298. doi: 10.1016/S0735-1097(03)00993-8 PubMedCrossRefGoogle Scholar
  10. 10.
    Porto I, Selvanayagam J, Ashar V, Neubauer S, Banning AP (2005) Safety of magnetic resonance imaging one to three days after bare metal and drug-eluting stent implantation. Am J Cardiol 96:366–368. doi: 10.1016/j.amjcard.2005.03.077 PubMedCrossRefGoogle Scholar
  11. 11.
    Kim RJ, Wu E, Rafael A et al (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445–1453. doi: 10.1056/NEJM200011163432003 PubMedCrossRefGoogle Scholar
  12. 12.
    Simonetti OP, Kim RJ, Fieno DS et al (2001) An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218:215–223PubMedGoogle Scholar
  13. 13.
    Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969. doi: 10.1016/S0735-1097(00)00804-4 PubMedCrossRefGoogle Scholar
  14. 14.
    Ricciardi MJ, Davidson CJ, Gubernikoff G et al (2003) Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 145:522–528. doi: 10.1067/mhj.2003.2 PubMedCrossRefGoogle Scholar
  15. 15.
    Mehran R, Aymong ED, Nikolsky E et al (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44:1393–1399PubMedGoogle Scholar
  16. 16.
    Liss P, Persson PB, Hansell P, Lagerqvist B (2006) Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 70:1811–1817. doi: 10.1038/ PubMedCrossRefGoogle Scholar
  17. 17.
    Thygesen K, Alpert JS, White HD et al (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653. doi: 10.1161/CIRCULATIONAHA.107.187397 PubMedCrossRefGoogle Scholar
  18. 18.
    Levey AS, Coresh J (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266CrossRefGoogle Scholar
  19. 19.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41. doi: 10.1159/000180580 PubMedCrossRefGoogle Scholar
  20. 20.
    De Luca G, Suryapranata H, Zijlstra F et al (2003) Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 42:991–997. doi: 10.1016/S0735-1097(03)00919-7 PubMedCrossRefGoogle Scholar
  21. 21.
    Boden WE, Eagle K, Granger CB (2007) Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 50:917–929. doi: 10.1016/j.jacc.2007.04.084 PubMedCrossRefGoogle Scholar
  22. 22.
    Sadeghi HM, Stone GW, Grines CL et al (2003) Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108:2769–2775. doi: 10.1161/01.CIR.0000103623.63687.21 PubMedCrossRefGoogle Scholar
  23. 23.
    Abdel-Aty H, Zagrosek A, Schulz-Menger J et al (2004) Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 109:2411–2416. doi: 10.1161/01.CIR.0000127428.10985.C6 PubMedCrossRefGoogle Scholar
  24. 24.
    Aletras AH, Tilak GS, Natanzon A et al (2006) Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 113:1865–1870. doi: 10.1161/CIRCULATIONAHA.105.576025 PubMedCrossRefGoogle Scholar
  25. 25.
    Kim RJ, Fieno DS, Parrish TB et al (1999) Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100:1992–2002PubMedGoogle Scholar
  26. 26.
    Kjoller E, Kober L, Jorgensen S, Torp-Pedersen C (1999) Long-term prognostic importance of hyperkinesia following acute myocardial infarction TRACE Study Group. Trandolapril cardiac evaluation. Am J Cardiol 83:655–659. doi: 10.1016/S0002-9149(98)00962-X PubMedCrossRefGoogle Scholar
  27. 27.
    Syed MA, Carlson K, Murphy M, Ingkanisorn WP, Rhoads KL, Arai AE (2006) Long-term safety of cardiac magnetic resonance imaging performed in the first few days after bare-metal stent implantation. J Magn Reson Imaging 24:1056–1061. doi: 10.1002/jmri.20740 PubMedCrossRefGoogle Scholar
  28. 28.
    Patel MR, Albert TS, Kandzari DE et al (2006) Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents. Radiology 240:674–680. doi: 10.1148/radiol.2403050740 PubMedCrossRefGoogle Scholar
  29. 29.
    Bolick DR, Hackel DB, Reimer KA, Ideker RE (1986) Quantitative analysis of myocardial infarct structure in patients with ventricular tachycardia. Circulation 74:1266–1279PubMedGoogle Scholar
  30. 30.
    de Bakker JM, Coronel R, Tasseron S et al (1990) Ventricular tachycardia in the infarcted, Langendorff-perfused human heart: role of the arrangement of surviving cardiac fibers. J Am Coll Cardiol 15:1594–1607PubMedCrossRefGoogle Scholar
  31. 31.
    Cury RC, Shash K, Nagurney JT et al (2008) Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Circulation 118:837–844. doi: 10.1161/CIRCULATIONAHA.107.740597 PubMedCrossRefGoogle Scholar
  32. 32.
    Shellock FG, Crues JV (2004) MR procedures: biologic effects, safety, and patient care. Radiology 232:635–652. doi: 10.1148/radiol.2323030830 PubMedCrossRefGoogle Scholar
  33. 33.
    Shellock FG, Shellock VJ (1999) Metallic stents: evaluation of MR imaging safety. Am J Roentgenol 173:543–547Google Scholar
  34. 34.
    Hug J, Nagel E, Bornstedt A, Schnackenburg B, Oswald H, Fleck E (2000) Coronary arterial stents: safety and artifacts during MR imaging. Radiology 216:781–787PubMedGoogle Scholar
  35. 35.
    Bottomley PA, Redington RW, Edelstein WA, Schenck JF (1985) Estimating radiofrequency power deposition in body NMR imaging. Magn Reson Med 2:336–349. doi: 10.1002/mrm.1910020404 PubMedCrossRefGoogle Scholar
  36. 36.
    Krams R, Verheye S, van Damme LC et al (2005) In vivo temperature heterogeneity is associated with plaque regions of increased MMP-9 activity. Eur Heart J 26:2200–2205. doi: 10.1093/eurheartj/ehi461 PubMedCrossRefGoogle Scholar
  37. 37.
    Remy-Jardin M, Dequiedt P, Ertzbischoff O et al (2005) Safety and effectiveness of gadolinium-enhanced multi-detector row spiral CT angiography of the chest: preliminary results in 37 patients with contraindications to iodinated contrast agents. Radiology 235:819–826. doi: 10.1148/radiol.2353040734 PubMedCrossRefGoogle Scholar
  38. 38.
    Mitka M (2007) MRI contrast agents may pose risk for patients with kidney disease. JAMA 297:253–254. doi: 10.1001/jama.297.3.253 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, B.V. 2009

Authors and Affiliations

  • Eric Larose
    • 1
  • Julie Côté
    • 1
  • Josep Rodés-Cabau
    • 1
  • Bernard Noël
    • 1
  • Gerald Barbeau
    • 1
  • Edith Bordeleau
    • 2
  • Santiago Miró
    • 2
  • Bernard Brochu
    • 2
  • Robert Delarochellière
    • 1
  • Olivier F. Bertrand
    • 1
  1. 1.Département multidisciplinaire de cardiologieInstitut universitaire de cardiologie et de pneumologie de Québec and Faculté de médecine de l’Université LavalQuebecCanada
  2. 2.Département d’imagerie médicaleInstitut universitaire de cardiologie et de pneumologie de Québec and Faculté de médecine de l’Université LavalQuebecCanada

Personalised recommendations